Evidence map›Paper›PMID 40923083›Full record

ArticleJTCVS open2025

Outcomes associated with remote, centralized ex vivo lung perfusion (rc-EVLP) for donor lungs in a real-world setting.

Anil J Trindade, Caitlin T Demarest, John W Stokes, Mathew Thomas, Ian Makey, Matthew Bacchetta, Jorge Mallea

Abstract read
In one paragraph

Article in JTCVS open, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Time as a Therapeutic Ally: The Promise of Long-Term Solid Organ and Tissue Perfusion.Transplant international : official journal of the European Society for Organ Transplantation · 2026
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Anil J TrindadeDivision of Allergy, Pulmonary and Critical Care Medicine, Vanderbilt University Medical Center, Nashville, Tenn.
Caitlin T DemarestDepartment of Thoracic Surgery, Vanderbilt University Medical Center, Nashville, Tenn.
John W StokesDepartment of Thoracic Surgery, Vanderbilt University Medical Center, Nashville, Tenn.
Mathew ThomasDepartment of Cardiothoracic Surgery, Mayo Clinic, Jacksonville, Fla.
Ian MakeyDepartment of Cardiothoracic Surgery, Mayo Clinic, Jacksonville, Fla.
Matthew BacchettaDepartment of Cardiac Surgery, Vanderbilt University Medical Center, Nashville, Tenn.
Jorge MalleaDepartment of Critical Care Medicine, Mayo Clinic, Jacksonville, Fla.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Objective: Ex vivo lung perfusion (EVLP) has resulted in a significant increase in the use of extended-criteria donor lungs without negatively impacting survival outcomes. However, in-house EVLP is resource-intensive, thereby limiting accessibility. Remote, centralized EVLP (rc-EVLP) has been used with acceptable outcomes in a highly protocolized feasibility study, although has not been assessed in a clinical setting. We characterized outcomes of rc-EVLP in a real-world setting and provide clinical associations related to donor use. Methods: We performed a dual-center, retrospective analysis of consecutive extended-criteria donor lungs evaluated on rc-EVLP between December 1, 2020, and March 20, 2023. Outcomes included transplantation rate, predictors of use, incidence of primary graft dysfunction grade 3 (PGD3), and 1-year survival. Group comparisons were examined using the Fisher exact test or Mann-Whitney Results: Eighty-two donors were assessed by rc-EVLP; 65% would've been excluded in the previous feasibility trial. Forty-six lungs (56%) were ultimately transplanted. Vascular permeability, static compliance, and oxygen transfer all were associated with use. PGD3 incidence in rc-EVLP recipients was 17%, whereas 1-year survival was 93%. Donor from circulatory death (DCD) lungs assessed by rc-EVLP had a use of 6 of 19 (33%). Greater preprocurement partial pressure of oxygen, arterial/fraction of inspired oxygen ratio and greater oxygen transfer and static compliance assessed after 2 hours on EVLP were associated with increased DCD use. Although PGD3 incidence with DCD lungs was 33%, there was 100% 1-year recipient survival. Finally, 2-hour EVLP assessments may be sufficient for determining donor quality for all lungs. Conclusions: Remote, centralized EVLP increases the use of extended-criteria donor lungs in a real-world setting and is associated with excellent outcomes. We provide objective criteria that are associated with the decision to use donor from brain death and DCD lungs assessed by rc-EVLP.

Indexed as

donors of circulatory death (DCD)donor useextended-criteria donorsex vivo lung perfusion (EVLP)lung transplantationremote-centralized EVLP

Identifiers

PMID40923083
PMCPMC12414424

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.